Big Pharma hardball may backfire, VC says

A biotech venture capitalist says Big Pharma's tough negotiating tactics when buying small drug developers threatens to stifle VC funding, especially for companies working on meds for chronic diseases. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.